Physician profile
Gary Schwartz
NPI 1780694752
$1,400.63
in general payments reported to CMS, 2019-2025
26 companies · $151 in 2025
The $151 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $366 · 2020: $211 · 2021: $183 · 2022: $244 · 2023: $81.23 · 2024: $164 · 2025: $151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $397.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $397.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orexo US, INC. | $184.49 | 2019-2020 | |
| Indivior INC. | $167.92 | 2019-2025 | Sublocade |
| Lilly USA, LLC | $141.19 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $93.75 | 2020-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals Lp | $72.63 | 2019-2021 | |
| Nevro Corp. | $65.24 | 2022 | |
| Inspire Medical Systems, INC. | $63.17 | 2024-2025 | Inspire |
| Eisai INC. | $57.81 | 2020-2022 | |
| Abbvie INC. | $57.73 | 2022-2024 | |
| Jazz Pharmaceuticals INC. | $56.22 | 2019-2021 | |
| Astellas Pharma US INC | $56.07 | 2024-2025 | Veozah |
| Xeris Pharmaceuticals, INC. | $48.51 | 2023 | Gvoke Hypopen |
| Pfizer INC. | $37.90 | 2019-2022 | |
| Vistapharm, INC. | $37.31 | 2021 | |
| Neurocrine Biosciences, INC. | $36.88 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $32.28 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $29.84 | 2020-2022 | |
| Ucb, INC. | $21.40 | 2022 | |
| Gilead Sciences, INC. | $21.13 | 2022 | |
| Amgen INC. | $19.66 | 2024 | Krystexxa |
| Azurity Pharmaceuticals, INC. | $19.28 | 2025 | Azmiro |
| Exact Sciences Corporation | $18.33 | 2025 | Cologuard Collection Kit |
| Rhodes Pharmaceuticals L.P. | $16.44 | 2019 | |
| Glaxosmithkline, LLC. | $15.49 | 2020 | |
| Merck Sharp & Dohme LLC | $15.18 | 2019 | |
| Vanda Pharmaceuticals INC. | $14.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Schwartz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.